You want to charge $1M for that gene ther­a­py? Here’s where you’re wrong

Spark Ther­a­peu­tics $ONCE doesn’t have a green light yet from the FDA to sell its gene ther­a­py for one small group of pa­tients with a ge­net­ic flaw that caus­es in­her­it­ed blind­ness. And com­pa­ny ex­ecs haven’t told any­one ex­act­ly what its whole­sale price will be for voreti­gene nepar­vovec.

But the odds look great for this treat­ment to quick­ly nab the first ap­proval for a vec­tor-de­liv­ered gene ther­a­py in the US — and it’s game on for a pric­ing de­bate that starts with an auc­tion fore­cast of $1 mil­lion per treat­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.